These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 8599036)
21. [Coronary heart disease prevention in type 2 diabetic patients. What is the value of fibrates?]. MMW Fortschr Med; 2002 Oct; 144(42):65. PubMed ID: 12534006 [No Abstract] [Full Text] [Related]
22. [Fenofibrate, efficacy and tolerance in long-term treatment (author's transl)]. Fromantin M; Gautier D; Quatre JM; Bon R Therapie; 1981; 36(4):473-6. PubMed ID: 7292431 [No Abstract] [Full Text] [Related]
23. [Treatment of atherosclerosis with hypolipidemic and antiuricemic agents]. Plastinina RA; Oleĭnik NA; Valeeva RM; Pavlova TN Sov Med; 1984; (1):83-7. PubMed ID: 6701660 [No Abstract] [Full Text] [Related]
24. Fenofibrate for hypertriglyceridemia. Med Lett Drugs Ther; 1998 Jul; 40(1030):68-9. PubMed ID: 9664930 [No Abstract] [Full Text] [Related]
25. [Verification of the lipid hypothesis by drug intervention]. Levy RI Ter Arkh; 1985; 57(11):33-5. PubMed ID: 3909475 [No Abstract] [Full Text] [Related]
27. Choice of lipid-regulating drugs. Med Lett Drugs Ther; 2001 May; 43(1105):43-8. PubMed ID: 11378632 [No Abstract] [Full Text] [Related]
28. Fenofibrate treatment in patients with primary biliary cirrhosis. Ohira H; Sato Y; Ueno T; Sata M Am J Gastroenterol; 2002 Aug; 97(8):2147-9. PubMed ID: 12190200 [No Abstract] [Full Text] [Related]
29. The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidaemic hypertensive patients. Coban E; Ozdogan M; Yazicioglu G; Sari R Int J Clin Pract; 2005 Apr; 59(4):415-8. PubMed ID: 15853856 [TBL] [Abstract][Full Text] [Related]
30. Effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in patients with diabetes mellitus and mixed dyslipidemia. Athyros VG; Kakafika AI; Karagiannis A; Mikhailidis DP Am J Cardiol; 2008 Jun; 101(11):1679-80. PubMed ID: 18489951 [No Abstract] [Full Text] [Related]
31. [Fenofibrate 250 SR Pharmavit in patients with mixed hyperlipoproteinemia. Results of a study of 189 patients from 13 centers in the Czech Republic]. Ceska R; Stulc T Cas Lek Cesk; 2000 Jun; 139(12):369-73. PubMed ID: 10953407 [TBL] [Abstract][Full Text] [Related]
32. A randomized placebo-controlled double-blind trial of lipid-lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate. Levin A; Duncan L; Djurdjev O; Shapiro RJ; Frohlich J; Belanger A; Dumas R; Ross S Clin Nephrol; 2000 Feb; 53(2):140-6. PubMed ID: 10711416 [TBL] [Abstract][Full Text] [Related]
33. FIELDS of dreams, fields of tears: a perspective on the fibrate trials. Wierzbicki AS Int J Clin Pract; 2006 Apr; 60(4):442-9. PubMed ID: 16620358 [TBL] [Abstract][Full Text] [Related]
34. Is fenofibrate a cost-saving treatment for middle-aged individuals with type II diabetes? An economic analysis of the FIELD Study. Carrington M; Stewart S Int J Cardiol; 2008 Jun; 127(1):51-6. PubMed ID: 17586072 [TBL] [Abstract][Full Text] [Related]
35. Effects of fenofibrate on C-reactive protein levels in hypertriglyceridemic patients. Kim CJ J Cardiovasc Pharmacol; 2006 Jun; 47(6):758-63. PubMed ID: 16810076 [TBL] [Abstract][Full Text] [Related]
36. Fenofibrate, probucol, and other lipid-lowering treatments in heart transplant recipients. de Lorgeril M; Boissonnat P; Salen P; Monjaud I; Dureau G J Heart Lung Transplant; 1996 May; 15(5):539-40. PubMed ID: 8771511 [No Abstract] [Full Text] [Related]
37. [Therapy effects of fenofibrate on alcoholic fatty liver and drug-induced fatty liver in rats]. Yan M; Meng FL; Lu RJ; Jia XQ; Zhao XC Zhonghua Gan Zang Bing Za Zhi; 2003 Feb; 11(2):86-9. PubMed ID: 12648401 [TBL] [Abstract][Full Text] [Related]
38. Effects of fenofibrate on inflammatory cytokines and blood pressure in patients with hypertriglyceridemia. Ye P; Li JJ; Su G; Zhang C Clin Chim Acta; 2005 Jun; 356(1-2):229-32. PubMed ID: 15936324 [No Abstract] [Full Text] [Related]
39. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus. Steiner G Am J Cardiol; 2008 Dec; 102(12A):28L-33L. PubMed ID: 19084087 [TBL] [Abstract][Full Text] [Related]
40. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Rosenson RS; Wolff DA; Huskin AL; Helenowski IB; Rademaker AW Diabetes Care; 2007 Aug; 30(8):1945-51. PubMed ID: 17483155 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]